drugset / Trial / NCT02415023
A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
An open-label, dose escalation and maximum tolerated dose (MTD) and/or recommended phase II dose (RPTD) study of fruquintinib combined with paclitaxel in patients with advanced gastric cancer who did not respond to first-line standard chemotherapy.
Timeline
- Start
- 2014-11-09
- Primary completion
- 2017-03-31
- Completion
- 2017-03-31
Publications
- Results 1. The 16th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) 2013 2. Elkerm YM, Elesaid A, AL-Batran, et al. Final results of a phase II trial of docetaxel-carboplatin- FU in locally advanced gastric carcinoma[abstract]. Presented at the 2008 gastrointestinal cancers symposium 2008.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 2 mg | — |
| Subject | Fruquintinib | Small molecule | 3 mg | — |
| Subject | Fruquintinib | Small molecule | 4 mg | — |
| Subject | Fruquintinib | Small molecule | 5 mg | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |